Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans grew its position in Twist Bioscience Co. (NASDAQ:TWST) by 54.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,505,753 shares of the company’s stock after purchasing an additional 532,040 shares during the quarter. Thrivent Financial for Lutherans owned approximately 2.52% of Twist Bioscience worth $69,972,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of TWST. Cibc World Markets Corp purchased a new position in shares of Twist Bioscience in the 4th quarter valued at $253,000. Swiss National Bank grew its position in shares of Twist Bioscience by 1.1% in the 4th quarter. Swiss National Bank now owns 115,200 shares of the company’s stock valued at $5,353,000 after buying an additional 1,200 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of Twist Bioscience by 59.6% in the 4th quarter. Farther Finance Advisors LLC now owns 5,429 shares of the company’s stock valued at $252,000 after buying an additional 2,028 shares during the last quarter. Wealthfront Advisers LLC purchased a new position in shares of Twist Bioscience in the 4th quarter valued at $209,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Twist Bioscience by 5.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,064 shares of the company’s stock valued at $793,000 after buying an additional 821 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TWST. Robert W. Baird raised their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. TD Cowen reissued a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research began coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $54.40.

Twist Bioscience Price Performance

Shares of TWST stock opened at $40.57 on Wednesday. The company has a market capitalization of $2.42 billion, a PE ratio of -12.00 and a beta of 2.15. The firm has a fifty day simple moving average of $45.54 and a 200-day simple moving average of $45.25. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.75) earnings per share. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 1,654 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $74,264.60. Following the completion of the transaction, the chief executive officer now owns 673,064 shares in the company, valued at approximately $30,220,573.60. This represents a 0.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Adam Laponis sold 5,886 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now owns 110,096 shares of the company’s stock, valued at $4,762,752.96. This represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,804 shares of company stock valued at $1,601,404. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.